The European Union on Thursday approved the highly contentious Alzheimer's medication Kisunla under strict conditions, with the drug's effectiveness hotly debated by the medical community.
Uncover the stories others won’t tell. Subscribe now for exclusive access
- Unlimited access to all premium content
- Uninterrupted ad-free browsing experience
- Mobile-optimized reading experience
- Weekly Newsletters
- MPesa, Airtel Money and Cards accepted